Project Grant K24HL189236
Award Date 8/5/26
Completion Date 5/31/31
Dollars Obligated $124K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University (doing business as Boston University Medical Campus) $837,000 in project grant funding on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into lung-specific mechanisms that enable Mycobacterium tuberculosis survival and progression in immunocompetent hosts. The project examines how dysplastic epithelial cells within pulmonary tuberculosis lesions...
- The National Heart Lung and Blood Institute awarded the President and Fellows of Harvard College (operating as Harvard Medical School) $3,793,888 under federal grant R01HL178712 on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research to identify host- and pathogen-specific risk factors for post-tuberculosis lung disease (PTLD) among successfully treated TB patients in Lima, Peru. The research team will evaluate 1,000 successfully...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $194,094 for a Project Grant (R03HL183275) on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the role of tuberculosis disclosure and stigma in TB care outcomes. The research examines how TB stigma—affecting 25–80 percent of people with TB globally—and non-disclosure to close contacts impede TB contact investigation, a critical step in disrupting...
- The National Heart Lung and Blood Institute awarded Duke University $518,544 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test a tailored pulmonary rehabilitation program for post-tuberculosis lung disease in resource-limited settings. The project will define clinical patterns of post-tuberculosis lung disease and associated outcomes to identify patients with greatest need for rehabilitation, develop a structured process for tailoring...
- The National Heart, Lung, and Blood Institute awarded $1.555 million to the University of Maryland, Baltimore on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model and treat chronic HIV-induced lung infections. The research investigates immune mechanisms underlying increased susceptibility to respiratory infections in people living with HIV. The project focuses on how chronic HIV infection impairs dendritic cell differentiation and function, hypothesizing...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $218,728 in project grant funding on March 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds spatial immunophenotyping of tuberculosis granulomas, with work performed at OHSU's Portland, Oregon campus through September 16, 2029. The project applies an extensive panel of Mycobacterium tuberculosis antigen-specific probes—including commercial antibodies, novel...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, San Francisco $358,032 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a systematic evaluation of post-tuberculosis lung disease (PTLD) and its relationship to HIV status. The project, titled "The Sequelae TB Study," will comprehensively characterize PTLD among a prospective cohort of TB survivors in Lusaka, Zambia. The...
- The National Heart Lung and Blood Institute awarded Northwestern University $654,762 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory T cell mechanisms limiting persistent inflammation during recovery from viral pneumonia. The award funds research into how FOXP3+ regulatory T cells orchestrate lung repair after viral pneumonia through expression of suppressive mediators, particularly the anti-inflammatory cytokine interleukin-10. The...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $768,600 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the lung macrophage efflux system in the pathogenesis of Mycobacterium tuberculosis. The research aims to identify host-directed therapeutic targets for tuberculosis treatment. The work focuses on two objectives: defining the role of the multidrug resistance transporter MDR1 in M. tuberculosis survival...